Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2022

Oct 25, 2022

BUY
$1.04 - $322.5 $2,288 - $709,500
2,200 New
2,200 $0
Q1 2018

May 11, 2018

SELL
$3.46 - $5.14 $14,878 - $22,102
-4,300 Reduced 87.76%
600 $0
Q4 2017

Jan 17, 2018

SELL
$4.0 - $6.54 $5,600 - $9,156
-1,400 Reduced 22.22%
4,900 $0
Q3 2017

Oct 17, 2017

BUY
$4.99 - $6.57 $31,437 - $41,391
6,300
6,300 $2,000

Others Institutions Holding TCRT

About Alaunos Therapeutics, Inc.


  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $607M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.